About Femta Pharmaceuticals, Inc.

SAN DIEGO--()--Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

Femta Pharmaceuticals, Inc. | LinkedIn

Femta Pharmaceuticals, Inc., a biotechnology company, intends to develop protein therapeutics

Learn about working at Femta Pharmaceuticals, Inc.

SAN DIEGO--()--Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

Femta Pharmaceuticals - Start Cortera

SAN DIEGO--()--Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).


SAN DIEGO--()-- Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).Femta Pharmaceuticals is focused on the development of best in class therapeutic monoclonal antibodies for the treatment of various disease states. Our monoclonal antibodies have applications in the areas of inflammation, autoimmune disease and oncology. Femta develops high affinity, high specificity monoclonal antibodies with improved effector functions as well as favorable safety and pharmacokinetic profiles. The high affinity of our antibodies will contribute to making our products more efficacious with better safety profiles, as well as potentially reducing drug dosage.Femta Pharmaceuticals is a business focused on the development of therapeutic monoclonal antibodies for the treatment of various disease states.

Femta Pharmaceuticals is focused on the rapid and cost effective development of highly effective and competitive therapeutic monoclonal antibodies for the treatment of various disease states. Our monoclonal antibodies have applications in the areas of inflammation, autoimmune disease and oncology. Femta develops high affinity, high specificity monoclonal antibodies with improved effector functions as well as favorable safety and pharmacokinetic profiles. The high affinity of our antibodies will contribute to making our products more efficacious with better safety profiles, as well as potentially reducing drug dosage. Femta’s product candidates and programs are protected by the company's extensive global intellectual property portfolio. More information about Femta can be found at .
Femta Pharmaceuticals

Learn more about Femta Pharmaceuticals

Femta Pharmaceuticals and Lonza Group of Switzerland have signed an agreement for the development and cGMP manufacturing of FM101, a high affinity monoclonal antibody in late pre-clinical development for the treatment of rheumatoid arthritis.

Femta Pharmaceuticals is a business focused on the development of therapeutic monoclonal ..

Femta Pharmaceuticals Company Profile | VentureDeal

Femta Pharmaceuticals has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA)

About Femta Pharmaceuticals, Inc

Femta Pharmaceuticals is a business focused on the development of therapeutic monoclonal antibodies for the treatment of various disease states.